161 related articles for article (PubMed ID: 9708565)
21. Radioimmunotherapy for non-Hodgkin's lymphoma.
Emmanouilides C
Semin Oncol; 2003 Aug; 30(4):531-44. PubMed ID: 12939722
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.
Song H; Du Y; Sgouros G; Prideaux A; Frey E; Wahl RL
J Nucl Med; 2007 Jan; 48(1):150-7. PubMed ID: 17204712
[TBL] [Abstract][Full Text] [Related]
23. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody.
Postema EJ; Oyen WJ; Boerman OC; Corstens FH
J Nucl Med; 2003 May; 44(5):853. PubMed ID: 12732690
[No Abstract] [Full Text] [Related]
24. Iodine-131 anti-B1 antibody therapy in non-Hodgkin's lymphoma: dosimetry and clinical implications.
Wahl RL
J Nucl Med; 1998 Aug; 39(8 Suppl):1S. PubMed ID: 9708563
[No Abstract] [Full Text] [Related]
25. Radioimmunotherapy for Non-Hodgkin's Lymphoma.
Rao AV; Akabani G; Rizzieri DA
Clin Med Res; 2005 Aug; 3(3):157-65. PubMed ID: 16160070
[TBL] [Abstract][Full Text] [Related]
26. Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody.
Shen S; DeNardo GL; Yuan A; Hartmann-Siantar C; O'Donnell RT; DeNardo SJ
Cancer Biother Radiopharm; 2005 Dec; 20(6):662-70. PubMed ID: 16398618
[TBL] [Abstract][Full Text] [Related]
27. Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET.
Torizuka T; Zasadny KR; Kison PV; Rommelfanger SG; Kaminski MS; Wahl RL
J Nucl Med; 2000 Jun; 41(6):999-1005. PubMed ID: 10855624
[TBL] [Abstract][Full Text] [Related]
28. Radioimmunotherapy of Non-Hodgkin's lymphoma.
Britton KE
J Nucl Med; 2004 May; 45(5):924-5. PubMed ID: 15136647
[No Abstract] [Full Text] [Related]
29. Radioimmunotherapy of non-Hodgkin's lymphoma revisited.
Goldenberg DM; Sharkey RM
J Nucl Med; 2005 Feb; 46(2):383-4. PubMed ID: 15695801
[No Abstract] [Full Text] [Related]
30. Radiolabeling of rituximab with (188)Re and (99m)Tc using the tricarbonyl technology.
Dias CR; Jeger S; Osso JA; Müller C; De Pasquale C; Hohn A; Waibel R; Schibli R
Nucl Med Biol; 2011 Jan; 38(1):19-28. PubMed ID: 21220126
[TBL] [Abstract][Full Text] [Related]
31. Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ⁹⁰Y and ¹¹¹In for domestic radioimmunotherapy and radioscintigraphy of non-Hodgkin's lymphoma.
Gholipour N; Jalilian AR; Khalaj A; Johari-Daha F; Yavari K; Sabzevari O; Khanchi AR; Akhlaghi M
Daru; 2014 Jul; 22(1):58. PubMed ID: 25074720
[TBL] [Abstract][Full Text] [Related]
32. Optimization of 90 Y-antiCD20 preparation for radioimmunotherapy.
Gholipour N; Vakili A; Radfar E; Jalilian AR; Bahrami-Samani A; Shirvani-Arani S; Ghannadi-Maragheh M
J Cancer Res Ther; 2013; 9(2):199-204. PubMed ID: 23771358
[TBL] [Abstract][Full Text] [Related]
33. [Systemic radiotherapy using monoclonal antibodies. Options and problems].
Sautter-Bihl ML; Wannenmacher M; Bihl H
Strahlenther Onkol; 1993 Jun; 169(6):358-65. PubMed ID: 8316939
[TBL] [Abstract][Full Text] [Related]
34. Combination therapy for non-Hodgkin's lymphoma: an opportunity for pharmaceutical care in a specialty practice.
Augustine SC; Norenberg JP; Colcher DM; Vose JM; Gobar LS; Dukat VJ; Hohenstein MA; Rutar FJ; Jacobson DA; Tempero MA
J Am Pharm Assoc (Wash); 2002; 42(1):93-100. PubMed ID: 11833524
[TBL] [Abstract][Full Text] [Related]
35. Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy.
Gates VL; Carey JE; Siegel JA; Kaminski MS; Wahl RL
J Nucl Med; 1998 Jul; 39(7):1230-6. PubMed ID: 9669400
[TBL] [Abstract][Full Text] [Related]
36. Revised Nuclear Regulatory Commission regulations for release of patients administered radioactive materials: outpatient iodine-131 anti-B1 therapy.
Siegel JA
J Nucl Med; 1998 Aug; 39(8 Suppl):28S-33S. PubMed ID: 9708568
[TBL] [Abstract][Full Text] [Related]
37. Radioimmunotherapy and NHL: nuclear medicine on the oncology team.
Knight N
J Nucl Med; 2002 Apr; 43(4):11N-12N, 25N, passim. PubMed ID: 11963928
[No Abstract] [Full Text] [Related]
38. Overview of studies on experimental radioimmunotherapy.
Knox SJ
Cancer Res; 1995 Dec; 55(23 Suppl):5832s-5836s. PubMed ID: 7493355
[TBL] [Abstract][Full Text] [Related]
39. Radioimmunotherapy in non-Hodgkin lymphoma: opinions of U.S. medical oncologists and hematologists.
Schaefer NG; Ma J; Huang P; Buchanan J; Wahl RL
J Nucl Med; 2010 Jun; 51(6):987-94. PubMed ID: 20484425
[TBL] [Abstract][Full Text] [Related]
40. The preparation of radiolabeled monoclonal antibodies for human use.
Tran L; Beijnen JH; Huitema AD
Hum Antibodies; 2009; 18(4):145-56. PubMed ID: 19996529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
